BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12640688)

  • 1. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
    Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
    Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
    Plaks V; Koudinova N; Nevo U; Pinthus JH; Kanety H; Eshhar Z; Ramon J; Scherz A; Neeman M; Salomon Y
    Neoplasia; 2004; 6(3):224-33. PubMed ID: 15153334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery.
    Schreiber S; Gross S; Brandis A; Harmelin A; Rosenbach-Belkin V; Scherz A; Salomon Y
    Int J Cancer; 2002 May; 99(2):279-85. PubMed ID: 11979445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide.
    Kelleher DK; Thews O; Scherz A; Salomon Y; Vaupel P
    Int J Oncol; 2004 Jun; 24(6):1505-11. PubMed ID: 15138594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
    Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
    Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
    Huang Z; Chen Q; Trncic N; LaRue SM; Brun PH; Wilson BC; Shapiro H; Hetzel FW
    Radiat Res; 2004 Jun; 161(6):723-31. PubMed ID: 15161347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
    Azzouzi AR; Lebdai S; Benzaghou F; Stief C
    World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.
    Colussi VC; Feyes DK; Mulvihill JW; Li YS; Kenney ME; Elmets CA; Oleinick NL; Mukhtar H
    Photochem Photobiol; 1999 Feb; 69(2):236-41. PubMed ID: 10048316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy of human squamous cell carcinoma in vitro and in xenografts in nude mice.
    Megerian CA; Zaidi SI; Sprecher RC; Setrakian S; Stepnick DW; Oleinick NL; Mukhtar H
    Laryngoscope; 1993 Sep; 103(9):967-75. PubMed ID: 8361317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy.
    Zilberstein J; Schreiber S; Bloemers MC; Bendel P; Neeman M; Schechtman E; Kohen F; Scherz A; Salomon Y
    Photochem Photobiol; 2001 Mar; 73(3):257-66. PubMed ID: 11281022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
    Chen B; Pogue BW; Zhou X; O'Hara JA; Solban N; Demidenko E; Hoopes PJ; Hasan T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):720-7. PubMed ID: 15701861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model.
    Fei B; Wang H; Meyers JD; Feyes DK; Oleinick NL; Duerk JL
    Lasers Surg Med; 2007 Oct; 39(9):723-30. PubMed ID: 17960753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.
    Whitacre CM; Feyes DK; Satoh T; Grossmann J; Mulvihill JW; Mukhtar H; Oleinick NL
    Clin Cancer Res; 2000 May; 6(5):2021-7. PubMed ID: 10815928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI.
    Gross S; Gilead A; Scherz A; Neeman M; Salomon Y
    Nat Med; 2003 Oct; 9(10):1327-31. PubMed ID: 14502284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.